Skip to content
Peptideworth

Ranked board

Peptides sold to men: who sells them, and what the trials say

The set of companies writing to men is not the set writing to women, and neither is the order. Four of these rows are the same molecule, bremelanotide, sold to men — and the approved product built on its trials, Vyleesi, carries the label sentence “VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men.” That is a regulatory fact quoted from the label, not a claim of ours about how anything works, and it is most of why this board's claim column reads as it does.

By Grant Delaney, Research Editor

Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.

What gets on this board

Every published review with at least one product whose own name or verbatim marketing copy addresses men. Read from the seller's page, never from the brand name — one company here with no gendered name at all sells a men's hormone programme alongside a menopause programme, and the one company that is literally two sex-segmented brands is on neither audience board. Only the products addressed to men are counted.

What decides the order

Ranked by how much of what each company sells is described accurately — the share of the products this board counts whose marketing claim matches the trials behind it. Ties go to the company with more matching claims, then to the one that names its pharmacy, then to the one that publishes a testing regime, and last of all to alphabetical order. Nothing is pinned, sponsored, or lifted into position.

What the grading found

1/8

Claims that match the trials

Across every one of these companies' products sold to men that we have graded.

3/7

Name their pharmacy

A telehealth brand is almost never the pharmacy that fills the order.

0

Publish a readable certificate

Of every company reviewed on this site, not just those on this board.

The ranking

Every product counted here was graded against the published trials for that molecule, using the company's own words about it. The three counts below are that grading, and they are the ranking — there is no score, no weighting and no adjustment behind them.

Only the products whose own copy addresses men are counted here. A product addressed to both audiences appears on this board and the women's board alike, which is why some companies are on both with different counts.

CompanyClaims vs. trialsDisclosesVisit
Eden

Checked August 2026

FDA letter — marketing

1/1100%

  • 0 reach past the trials
  • 0 with no trial behind them
Testing shown
Visit
1st Optimal

Checked August 2026

0/10%

  • 0 reach past the trials
  • 1 with no trial behind them
Pharmacy namedTesting shown
Visit
Invigor Medical

Checked August 2026

0/10%

  • 1 reach past the trials
  • 0 with no trial behind them
Pharmacy namedTesting shown
Visit
PeptidesRx

Checked August 2026

0/10%

  • 1 reach past the trials
  • 0 with no trial behind them
Pharmacy namedTesting shown
Not linked
Valhalla Vitality

Checked August 2026

0/20%

  • 1 reach past the trials
  • 1 with no trial behind them
Testing shown
Visit
Hone Health

Checked August 2026

0/10%

  • 0 reach past the trials
  • 1 with no trial behind them
Nothing published
Visit
Lighter You

Checked August 2026

0/10%

  • 1 reach past the trials
  • 0 with no trial behind them
Nothing published
Visit

How a claim is graded, and what moves a compound between evidence tiers, is on our methodology page.

What this board does not measure

Whether it works

A company can describe a weakly-evidenced product accurately and rank well here. What the evidence says about each molecule is on its own graded compound page, and the two questions are deliberately kept apart.

Clinical care

We read public pages. We have not been a patient of any of these companies, have not assessed a consultation, and publish no quality score of any kind.

Price

Prices appear on a review as a note where a company publishes one, and they are not part of this ranking. A cheaper company is not lower here and a dearer one is not higher.

Product quality

Not one company reviewed here publishes a certificate of analysis a customer can read. Until that changes, nothing on this site can tell you what is in a vial.

Considered, and not on this board

11 companies were inside this board's candidate net and did not meet its rule. Each one has a published review here, and none was left off for an unflattering result.

  • AgelessRx

    None of AgelessRx's 6 product pages addresses men. Its copy for Rapamycin (sirolimus), Semaglutide, Sermorelin, Nicotinamide adenine dinucleotide (NAD+) and 1 more is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • Auren Rx

    None of Auren Rx's 6 product pages addresses men. Its copy for Semaglutide, Tirzepatide, GHK-Cu, Glutathione and 2 more is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • Defy Medical

    None of Defy Medical's 3 product pages addresses men. Its copy for Sermorelin, Semaglutide, Bremelanotide (PT-141) is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • Joi + Blokes

    None of Joi + Blokes's 5 product pages addresses men. Its copy for Tirzepatide, Semaglutide, Sermorelin, Vasoactive intestinal peptide (VIP) and 1 more is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • Maximus

    None of Maximus's 5 product pages addresses men. Its copy for Oxytocin, Sermorelin, Tesamorelin, Semaglutide and 1 more is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • NovoCare Pharmacy

    None of NovoCare Pharmacy's 3 product pages addresses men. Its copy for Semaglutide is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • Regenics

    None of Regenics's 6 product pages addresses men. Its copy for Tesamorelin, BPC-157, Epithalon (epitalon), MOTS-c and 2 more is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • Rehydra+ Wellness

    None of Rehydra+ Wellness's 3 product pages addresses men. Its copy for Semaglutide, Tirzepatide, Nicotinamide adenine dinucleotide (NAD+) is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • The Edit Health

    None of The Edit Health's 6 product pages addresses men. Its copy for Semaglutide, Tirzepatide, GHK-Cu, Sermorelin and 2 more is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • Trellis Vitality

    None of Trellis Vitality's 5 product pages addresses men. Its copy for Semaglutide, Tirzepatide, Tesamorelin, Nicotinamide adenine dinucleotide (NAD+) and 1 more is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

  • Vyvron

    None of Vyvron's 5 product pages addresses men. Its copy for Sermorelin, Nicotinamide adenine dinucleotide (NAD+), Methylcobalamin with methionine, inositol and choline (B12-MIC), Semaglutide and 1 more is written to no particular audience, so there is no claim made to men here for us to grade — a fact about its marketing, not about who it will treat.

Frequently asked questions

Why do so many rows here score zero?

Because the largest single product category on this board is bremelanotide sold to men, and the trial programme behind that molecule was run in premenopausal women. A claim can be graded as unsupported while the molecule itself has excellent evidence — for a different population and a different endpoint. Each review sets out the searches behind its own verdict.

Is this the same board as the women's one with a different heading?

No, and it would be worth nothing if it were. The two boards are built from different products, hold different companies, and come out in different orders — because the rule reads each seller's own copy rather than the brand over the door. Companies appearing on both are the ones whose product pages address both audiences.

Nothing pinned

Ranked by how much of what each company sells is described accurately — the share of the products this board counts whose marketing claim matches the trials behind it. Ties go to the company with more matching claims, then to the one that names its pharmacy, then to the one that publishes a testing regime, and last of all to alphabetical order. Nothing is pinned, sponsored, or lifted into position.

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.